DYN Dyne Therapeutics

Dyne Therapeutics to Present at 39th Annual J.P. Morgan Healthcare Conference

Dyne Therapeutics to Present at 39th Annual J.P. Morgan Healthcare Conference

WALTHAM, Mass., Jan. 05, 2021 (GLOBE NEWSWIRE) -- . (Nasdaq: DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that Joshua Brumm, president and chief executive officer, and Romesh Subramanian, Ph.D., chief scientific officer, are scheduled to present at the virtual 39th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13, 2021 at 10:00 a.m. ET.

A live webcast will be available in the Investors & Media section of Dyne’s website at and a replay will be accessible for 90 days following the presentation.

About Dyne Therapeutics

Dyne Therapeutics is building a leading muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases. The Company utilizes its proprietary FORCE™ platform to overcome the current limitations of muscle tissue delivery with modern oligonucleotide therapeutic candidates. Dyne is developing a broad portfolio of therapeutics for muscle diseases, including programs in myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD). For more information, please visit , and follow us on ,  and .

Contact:

Dyne Therapeutics

Amy Reilly



857-341-1203



EN
05/01/2021

Underlying

DYNDyne Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Dyne Therapeutics

 PRESS RELEASE
Free
DYN Dyne Therapeuti...

Dyne Therapeutics to Present at Upcoming Investor Conferences

Dyne Therapeutics to Present at Upcoming Investor Conferences WALTHAM, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- . (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that management is scheduled to present at the following upcoming investor conferences: Guggenheim 2nd Annual Healthcare Innovation Conference, fireside chat on Monday, November 10, 2025 at 10:00 a.m. ET in Boston, MAStifel 2025 Healthcare Conference, fireside chat on Tuesday, November 11, 2025 at 9:20 a.m. ET i...

6h / 25m 1 EN
Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke
EUR 43.35
PEP PEPSICO INC.
WAT Waters Corporat... ... (+25)

Vermilion Booster Shots: Attractive bottom-fishing stocks

For investors looking for bottom-fishing candidates; stocks that are breaking downtrends, exhibiting ascending reaction lows, and showing stabilizing relative strength.

PEP PEPSICO INC.
WAT WATERS CORPORATION
TECH BIO-TECHNE CORPORATION
SSTK SHUTTERSTOCK INC.
EVEREST RE GROUP LTD.
FORM FORMFACTOR INC.
COLB COLUMBIA BANKING SYSTEM INC.
ANDE ANDERSONS INC.
ACHC ACADIA HEALTHCARE COMPANY INC.
MET METLIFE INC.
HP HELMERICH & PAYNE INC.
RELL RICHARDSON ELECTRONICS LTD.
COKE COCA-COLA CONSOLIDATED INC.
AMRK AMARK PRECIOUS METALS
BLNK BLINK CHARGING
CABA CABALETTA BIO
DYN DYNE THERAPEUTICS
CGEM CULLINAN ONCOLOGY INC
CVRX CVRX INC
ABSI ABSCI CORP
PNI PIMCO NEW YORK MUNICIPAL FUND II
EE EXCELERATE ENERGY INC
RDZN ROADZEN INC
ARDT ARDENT HEALTH PARTNERS INC
FCEL FUELCELL ENERGY INC.
10/17/25 October 17, 2025 1 EN
 PRESS RELEASE
Free
DYN Dyne Therapeuti...

Dyne Therapeutics Announces Additional One-Year Clinical Data Demonstr...

Dyne Therapeutics Announces Additional One-Year Clinical Data Demonstrating Functional Improvement from Phase 1/2 ACHIEVE Trial of Zeleciment Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1) - Robust improvement demonstrated across diverse set of clinical measures - - Patient-reported outcomes support clinical meaningfulness of improvements in function and strength - - Meaningful improvements in overall disease burden reported by both patients and physicians - WALTHAM, Mass., Oct. 06, 2025 (GLOBE NEWSWIRE) -- . (Nasdaq: DYN), a clinical-stage company focused on delivering fu...

October 6, 2025 1 EN
 PRESS RELEASE
Free
DYN Dyne Therapeuti...

Dyne Therapeutics Appoints Brian Posner to its Board of Directors

Dyne Therapeutics Appoints Brian Posner to its Board of Directors WALTHAM, Mass., Oct. 02, 2025 (GLOBE NEWSWIRE) -- . (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced the appointment of Brian Posner to its Board of Directors. Mr. Posner brings 35 years of executive, investment and board leadership expertise to the company. “Brian is joining our Board during a pivotal phase, as we transition to becoming a fully integrated biotechnology company poised to commercialize our f...

October 2, 2025 1 EN
 PRESS RELEASE
Free
DYN Dyne Therapeuti...

Dyne Therapeutics Receives Orphan Drug Designation in Japan for DYNE-2...

Dyne Therapeutics Receives Orphan Drug Designation in Japan for DYNE-251 in Duchenne Muscular Dystrophy - Data from ongoing DELIVER trial demonstrated sustained functional improvement through 18 months; results from Registrational Expansion Cohort expected late 2025 - WALTHAM, Mass., Sept. 29, 2025 (GLOBE NEWSWIRE) -- . (Nasdaq: DYN), a clinical-stage company, today announced that the Ministry of Health, Labour and Welfare (MHLW) in Japan has granted Orphan Drug designation for DYNE-251 in individuals with Duchenne muscular dystrophy (DMD) who have mutations in the DMD gene that are amen...

September 29, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch